What Xyzal Treats: Main Uses and Benefits

The therapeutic utility of Xyzal (levocetirizine) is used for managing the key symptoms of allergic conditions. This is relevant for easing symptoms that interfere with daily functioning and is commonly used across conditions presenting with acute episodes or recurrent manifestations.

The medication is applied in addressing symptom clusters associated with seasonal and perennial allergic rhinitis and the uncomplicated skin manifestations of chronic idiopathic urticaria (long-term hives). This assists with managing symptoms related to physical discomfort like persistent sneezing, a runny or itchy nose, watery eyes, and intense skin itching.

“The supportive relief provided may assist patients in coping more steadily with these recurrent, distressing manifestations.”

This overall approach provides supportive relief for allergy patterns that require management with daily consistency. The daily use may assist with maintaining functional stability, thereby contributing to easing the overall symptom load and supports general well-being during symptomatic periods.

---

Quick Fact: Relief for Persistent Allergic Discomfort

Eligibility Map: Who can and cannot use Xyzal — Official Regulatory Information

The eligibility for Xyzal (levocetirizine) is determined by regulatory-mandated population constraints focusing on age, immune history, and organ function. The medicine is contraindicated for patients with a known hypersensitivity to levocetirizine, its active components, or related compounds like cetirizine or hydroxyzine.

Contraindications and Restrictions

Population Group	Eligibility Status	Basis for Constraint
Adults and Adolescents ( 12 years)	Approved	Standard labeled use.
Infants ( < 6 months)	Not Recommended	Safety and effectiveness have not been established.
End-Stage Renal Disease (ESRD)	Contraindicated	Creatinine clearance CLcr < 10 mL/min is a formal prohibition.
Pediatric with Renal Impairment	Contraindicated	Applies to children aged 6 months to 11 years with impaired kidney function.
Lactating Women	Not Recommended	Expected excretion of levocetirizine into breast milk.

Use is approved for pediatric patients down to 6 months of age (oral solution only), but the film-coated tablet is not recommended for those under 6 years. For all patients with less severe renal impairment, use is restricted and requires dose adjustment. Caution is advised for older adults and individuals with predisposing factors for urinary retention.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of levocetirizine primarily through restrictions on co-use with central nervous system depressants and through constraints related to the medicine’s elimination pathway.

Pharmacodynamic and Substance Interactions

The co-administration of Xyzal with alcohol or other CNS depressants (such as sedatives or tranquilizers) must be avoided due to the potential for an additive pharmacodynamic effect. This combination can lead to further impairment of central nervous system performance, reducing alertness.

Pharmacokinetic and Clearance Constraints

Levocetirizine is substantially excreted by the kidneys; consequently, it is contraindicated in patients diagnosed with End-Stage Renal Disease (creatinine clearance less than 10 mL/min) and in pediatric patients with renal impairment. Dose adjustments are formally recommended for elderly patients with moderate to severe renal impairment.

Regarding drug-drug interactions, co-administration of the parent compound, cetirizine, with Ritonavir resulted in an increased plasma AUC and decreased clearance. Similarly, Theophylline co-administration with cetirizine caused a small reduction in its clearance. Studies show levocetirizine is unlikely to produce pharmacokinetic interactions through major CYP liver enzymes. Furthermore, while Xyzal can be taken with food, a high-fat meal will delay the time to peak concentration and decrease the peak concentration ( Cmax), though the total drug exposure ( AUC) remains unaffected.

Xyzal, containing the active enantiomer levocetirizine, functions primarily as a highly selective second-generation H1 histamine receptor inverse agonist.

The compound exhibits elevated affinity for the peripheral H1 receptor, a G-protein-coupled receptor (GPCR) predominantly expressed on smooth muscles, vascular endothelial cells, and glandular cells. By binding to the H1 receptor, levocetirizine stabilizes the receptor in its inactive conformation, thus reducing or eliminating the constitutive activity and blocking the binding and activity of the endogenous agonist, histamine.

This H1 receptor inverse agonism prevents the downstream intracellular cascade typically mediated by histamine binding, which involves Gq protein activation, subsequent phospholipase C activation, and release of intracellular calcium. The resulting systemic physiological modulation includes decreased capillary permeability and inhibition of histamine-induced smooth muscle contraction and vasodilation.

Levocetirizine (Xyzal) is intended strictly for oral administration, available as a 5 mg film-coated tablet and an oral solution (2.5 mg/5 mL). The general principle of use follows a once daily frequency pattern.

For adults and pediatric patients aged 12 years and older, the standard approved regimen is 5 mg taken once per day. For younger children aged 6 to 11 years, the official use requires a dose of 2.5 mg once daily.

Administration Conditions and Adjustments

The medication may be administered with or without food, providing flexibility in the daily schedule. The tablet should be swallowed whole with a liquid, and the oral solution must be measured using an accurate, calibrated dosing device to ensure proper intake. The duration of use varies, ranging from short-term use for acute episodes to long-term use for chronic conditions.

A key procedural constraint involves the patient’s renal function. For patients with moderate to severe renal impairment (Creatinine Clearance < 50 mL/min), a reduction in dose or frequency is required as part of the official use protocol, which also applies when determining appropriate dosing for older adults. If a dose is missed, the procedural rule is to continue with the next scheduled dose at the usual time, without taking an extra dose.

Research Evidence / Overview of Studies for Xyzal

Evidence for Use in Seasonal Allergic Rhinitis (SAR)

Research has explored the use of levocetirizine for managing symptoms associated with Seasonal Allergic Rhinitis (SAR), which is characterized by fluctuating or episodic manifestations. The primary evidence base for this application includes short-term, placebo-controlled Randomized Controlled Trials (RCTs), along with subsequent Systematic Reviews. These studies primarily focused on populations of adults, adolescents, and children (ages six and older) who were experiencing heightened symptom activity.

In these trials, researchers primarily examined outcomes related to physical discomfort and changes in daily functioning. Studies monitored patient-reported outcomes describing perceived discomfort, particularly the Total Symptom Score (TSS), which is used in research exploring how symptoms change over time. Findings describe patterns observed in the studies, where patient-reported scores were recorded over the course of the short study periods, typically lasting only two weeks.

Evidence for Use in Chronic Idiopathic Urticaria (CIU)

Levocetirizine was studied for the uncomplicated skin manifestations of Chronic Idiopathic Urticaria (CIU), a condition characterized by fluctuating or episodic manifestations such as hives (wheals) and intense itching. The research includes short- to intermediate-term, placebo-controlled RCTs which were applied in research contexts involving fluctuating or unstable symptoms. Studies monitored responses over defined time intervals, enrolling adults and children with the condition.

The studies explored outcomes linked to inflammatory or irritative states, focusing specifically on objective measures like the size and number of wheals and patient-reported outcomes describing perceived discomfort, known as pruritus (itching) severity. Research describes that the severity of itching was tracked daily by patients and formally assessed by clinicians throughout the trial duration. Findings describe patterns observed in the studies related to the measurement of these skin symptoms during the period of administration.

Long-Term Research and Specific Patient Populations

Research has explored short-term symptom changes for the episodic nature of SAR and has conducted longer studies for the chronic patterns of PAR and CIU. However, when considering continuous use over many years, there is limited information for long-term outcomes regarding the sustained effects of levocetirizine. The available evidence tends to focus on short- to intermediate-term efficacy, meaning durability of response and any changes in effect over a period exceeding six months are not well characterized in the core regulatory research record.

Levocetirizine was evaluated in studies involving several age groups. The core body of evidence includes dedicated trials that enrolled pediatric patients (children aged 6 to 11 years) for both allergic rhinitis and chronic idiopathic urticaria. Specific research exploring outcomes monitoring physiological strain or stress in older adults (e.g., those over 75) is often limited, meaning the core results should be contextualized against the populations studied in the main clinical program.

Key Studies & References

1. Xyzal (levocetirizine dihydrochloride) Drug Label Information (DailyMed - NIH)

Storage and Disposal Requirements for Xyzal

Xyzal (levocetirizine dihydrochloride) tablets and oral solution must be kept at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). Temporary temperature excursions between 15 C and 30 C (59 F and 86 F) are permitted.

The medicine must be stored out of reach of children. Packaging integrity is mandatory; do not use tablets if the blister unit is torn or the oral solution if the inner seal is missing. For the oral solution, the product has a restricted 3-month shelf-life after first opening.

Disposal of any unused or expired product must be done in accordance with local requirements for medicinal products.